Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Früh, Martin; Betticher, Daniel C; Stupp, Roger; Xyrafas, Alexandros; Peters, Solange; Ris, Hans Beat; Mirimanoff, Rene Olivier; Ochsenbein, Adrian F; Schmid, Ralph; Matzinger, Oscar; Stahel, Rolf A; Weder, Walter; Guckenberger, Matthias; Rothschild, Sacha I; Lardinois, Didier; Mach, Nicholas; Mark, Michael; Gautschi, Oliver; Thierstein, Sandra; Biaggi Rudolf, Christine; Pless, Miklos (2019). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of Thoracic Oncology, 14(1):115-123.

Al Sayed, Mohamad F; Ruckstuhl, Carla A; Hilmenyuk, Tamara; Claus, Christina; Bourquin, Jean-Pierre; Bornhauser, Beat C; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F (2017). CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. Blood, 130(3):297-309.

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian F; Swiss Group for Clinical Cancer Research (SAKK) (2017). Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: Update from the swiss group for clinical cancer research (SAKK) 19/09 trial. Clinical Lung Cancer, 18(3):303-309.

Gautschi, Oliver; Mach, Nicholas; Rothschild, Sacha I; Li, Qiyu; Stahel, Rolf A; Zippelius, Alfred; Cathomas, Richard; Früh, Martin; Betticher, Daniel C; Peters, Solange; Rauch, Daniel; Feilchenfeldt, Jonas; Bubendorf, Lukas; Savic, Spasenija; Jaggi, Rolf; Leibundgut, Elisabeth Oppliger; Largiadèr, Carlo; Brutsche, Martin; Pilop, Christiane; Stalder, Lukas; Pless, Miklos; Ochsenbein, Adrian F (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer, 16(5):358-365.

This list was generated on Sat Mar 23 08:14:53 2019 CET.